Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
10/20Stock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, Heron The.. 
10/20Sanofi : Stock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, .. 
10/20Regeneron Pharmaceuticals, Inc. $REGN Earns Hold Rating from J P Morgan Chase.. 
10/19Lord Abbett & CO. LLC Purchases Shares of 105,736 Regeneron Pharmaceutica.. 
10/19Regeneron Pharmaceuticals, Inc. $REGN Earns Buy Rating from Canaccord Genuity.. 
10/19$SAN - Jefferies Group LLC Analysts Give Sanofi SA #SAN a €90.00 Pri.. 
10/18Sanofi SA given €96.00 PT by Deutsche Bank AG. buy rating.  
10/18Video: Regeneron Pharmaceuticals  
10/18Analysts’ Weekly Ratings Updates for Regeneron Pharmaceuticals $REGN  
10/17$TSPT AIMT: Aimmune Announces Clinical Collaboration with Regeneron/Sanofi fo.. 
10/17Sanofi SA given €82.00 PT by Goldman Sachs Group, Inc. (The). neutral rating... 
10/17Sanofi cancer executive jumps ship to Silicon Therapeutics
1
10/17Sanofi, Merck, Blueprint and Exelixis vet Christopher Winter has been appoint.. 
10/17$REGN - Canaccord Genuity Reaffirms "Buy" Rating for Regeneron Pharmaceutical.. 
10/17Regeneron Pharmaceuticals's buy rating reiterated at Canaccord Genuity.  
10/17Regeneron-Sanofi drug succeeds mid-stage study  
10/17CORRECTED-UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study  
10/16Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients .. 
10/16Regeneron and Sanofi's Dupixent shows treatment effect in mid-stage eosinophi.. 
10/16Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis: Market Real.. 
10/16Regeneron-Sanofi food allergy drug succeeds mid-stage study: Yahoo/Reuters  
10/16#Aimmune teams with #Regeneron, #Sanofi on #peanut #allergy drug
2
10/16Aimmune teams with Regeneron, Sanofi on peanut allergy drug
1
10/16Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in.. 
10/16Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in.. 
10/16Aimmune teams with Regeneron, Sanofi on peanut allergy drug  
10/16Aimmune teams with Regeneron, Sanofi on peanut allergy drug  
10/16Regeneron-Sanofi food allergy drug succeeds mid-stage study  
10/16Sanofi SA given €90.00 PT by Jefferies Group LLC. neutral rating.  
10/16UPDATE 1-Regeneron-Sanofi food allergy drug succeeds mid-stage study  
10/16Another win for #dupilumab as #Regeneron-#Sanofi drug succeeds in mid-stage f..
1
10/16Regeneron-Sanofi throat infection drug succeeds key study
2
10/16Regeneron-Sanofi throat infection drug succeeds key study  
10/16Regeneron-Sanofi throat infection drug succeeds key study  
10/16$REGN Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilu.. 
10/16Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Reg..
1
10/16Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Reg.. 
10/16Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Reg.. 
10/15Public Employees Retirement System of Ohio Raises Holdings in Regeneron Pharm.. 
10/14Sanofi $SNY Shares Sold by Raab & Moskowitz Asset Management LLC  
10/14Bank of Nova Scotia Has $8.44 Million Stake in Regeneron Pharmaceuticals, Inc.. 
10/14Head-To-Head Comparison: Sanofi $SNY & Its Rivals  
10/13#2 -- Four years after it imploded at Sanofi, John Hood is resurrecting the m..
3
10/13Regeneron Pharmaceuticals, Inc. $REGN Downgraded by Zacks Investment Research.. 
10/13Impact bags $22M to save ex-Sanofi drug from trial limbo:
1
10/13Four years after it imploded at Sanofi, John Hood is resurrecting the myelofi.. 
10/13Sanofi killed his PhIII myelofibrosis drug, and now John Hood is bringing it ..
6
10/13Four years after it imploded at Sanofi, John Hood is resurrecting the myelofi..
2
10/13Sanofi commits €170M to expand flu vaccines production: Biopharma Dive  
10/12Sanofi builds on its top spot in flu vaccines with $200M plant investment
4
More tweets
Qtime:207
Financials (€)
Sales 2017 36 177 M
EBIT 2017 9 601 M
Net income 2017 8 158 M
Debt 2017 4 345 M
Yield 2017 3,61%
P/E ratio 2017 12,85
P/E ratio 2018 17,48
EV / Sales 2017 3,05x
EV / Sales 2018 2,97x
Capitalization 106 B
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 86,7 €
Spread / Average Target 3,4%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI9.90%124 704
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223